First Heartland Consultants’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,051
| Closed | -$620K | – | 551 |
|
|
2025
Q4 | $620K | Buy |
5,051
+202
| +4% | +$24.5K | 0.05% | 250 |
|
|
2025
Q3 | $538K | Buy |
4,849
+175
| +4% | +$19.9K | 0.04% | 270 |
|
|
2025
Q2 | $518K | Buy |
4,674
+584
| +14% | +$62.2K | 0.05% | 258 |
|
|
2025
Q1 | $458K | Sell |
4,090
-1,351
| -25% | -$139K | 0.05% | 253 |
|
|
2024
Q4 | $503K | Buy |
5,441
+19
| +0.4% | +$1.71K | 0.05% | 232 |
|
|
2024
Q3 | $456K | Sell |
5,422
-53
| -1% | -$4.04K | 0.05% | 261 |
|
|
2024
Q2 | $376 | Buy |
5,475
+1,464
| +36% | +$97.7K | 0.03% | 306 |
|
|
2024
Q1 | $294K | Buy |
4,011
+126
| +3% | +$9.69K | 0.03% | 338 |
|
|
2023
Q4 | $415K | Buy |
3,885
+88
| +2% | +$6.85K | 0.05% | 236 |
|
|
2023
Q3 | $285K | Buy |
3,797
+17
| +0.4% | +$1.31K | 0.04% | 292 |
|
|
2023
Q2 | $291K | Sell |
3,780
-3,518
| -48% | -$281K | 0.04% | 292 |
|
|
2023
Q1 | $606K | Sell |
7,298
-67
| -0.9% | -$5.55K | 0.09% | 181 |
|
|
2022
Q4 | $632K | Sell |
7,365
-528
| -7% | -$41.8K | 0.1% | 169 |
|
|
2022
Q3 | $486 | Sell |
7,893
-1,166
| -13% | -$73.5K | 0.04% | 191 |
|
|
2022
Q2 | $559K | Buy |
9,059
+1,256
| +16% | +$77.8K | 0.09% | 174 |
|
|
2022
Q1 | $463K | Buy |
7,803
+556
| +8% | +$35.5K | 0.07% | 191 |
|
|
2021
Q4 | $526 | Sell |
7,247
-307
| -4% | -$21.1K | 0.02% | 189 |
|
|
2021
Q3 | $528K | Buy |
7,554
+1,129
| +18% | +$79.3K | 0.08% | 193 |
|
|
2021
Q2 | $442K | Buy |
6,425
+1,900
| +42% | +$127K | 0.07% | 231 |
|
|
2021
Q1 | $292K | Buy |
4,525
+622
| +16% | +$40.1K | 0.05% | 285 |
|
|
2020
Q4 | $227K | Sell |
3,903
-85
| -2% | -$5.13K | 0.04% | 300 |
|
|
2020
Q3 | $252K | Buy |
3,988
+482
| +14% | +$33.4K | 0.05% | 237 |
|
|
2020
Q2 | $270K | Sell |
3,506
-223
| -6% | -$17.1K | 0.05% | 224 |
|
|
2020
Q1 | $279K | Buy |
+3,729
| New | +$258K | 0.07% | 194 |
|
|
2018
Q2 | – | Sell |
-3,046
| Closed | -$230K | – | 246 |
|
|
2018
Q1 | $230K | Sell |
3,046
-3
| -0.1% | -$238 | 0.07% | 240 |
|
|
2017
Q4 | $218K | Sell |
3,049
-5,878
| -66% | -$446K | 0.07% | 252 |
|
|
2017
Q3 | $723K | Hold |
8,927
| – | – | 0.18% | 160 |
|
|
2017
Q2 | $632K | Buy |
8,927
+39
| +0.4% | +$2.6K | 0.16% | 169 |
|
|
2017
Q1 | $604K | Sell |
8,888
-4,910
| -36% | -$345K | 0.17% | 167 |
|
|
2016
Q4 | $988K | Sell |
13,798
-5,769
| -29% | -$429K | 0.3% | 92 |
|
|
2016
Q3 | $1.55M | Buy |
19,567
+4,844
| +33% | +$393K | 0.45% | 53 |
|
|
2016
Q2 | $1.23K | Sell |
14,723
-12,921
| -47% | -$1.15M | 0.13% | 62 |
|
|
2016
Q1 | $2.54M | Sell |
27,644
-2,033
| -7% | -$183K | 0.97% | 17 |
|
|
2015
Q4 | $3M | Sell |
29,677
-10,668
| -26% | -$1.11M | 1.14% | 13 |
|
|
2015
Q3 | $3.96M | Sell |
40,345
-929
| -2% | -$103K | 1.65% | 11 |
|
|
2015
Q2 | $4.83K | Sell |
41,274
-2,099
| -5% | -$229K | 1.31% | 12 |
|
|
2015
Q1 | $4.26M | Buy |
43,373
+16,345
| +60% | +$1.66M | 1.62% | 10 |
|
|
2014
Q4 | $2.55M | Buy |
27,028
+18,920
| +233% | +$1.96M | 1.05% | 14 |
|
|
2014
Q3 | $863K | Buy |
+8,108
| New | +$794K | 0.38% | 77 |
|
Other funds holding GILD
VCM
VPM
First Heartland Consultants's GILD Position: Q1 2026 in Review
First Heartland Consultants sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 5,051 shares — an estimated $620K sold.
First Heartland Consultants first reported a position in GILD in Q3 2014 and held it in 39 quarters. The position peaked at $4.26M in Q1 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- First Heartland Consultants reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
- First Heartland Consultants sold 5,051 Gilead Sciences shares in Q1 2026, an estimated $620K.
- First Heartland Consultants first reported a position in Gilead Sciences in Q3 2014 and held it in 39 quarters.
- First Heartland Consultants's Gilead Sciences position peaked at $4.26M in Q1 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on First Heartland Consultants's 13F filing for Q1 2026, filed 8 Apr 2026.